Document is current
Any future updates will be listed below
-
Authors
Gustafsson, Finn https://orcid.org/0000-0003-2144-341X
- License Information
-
More Information
Article History
First Online: 25 August 2023
Competing interests
: F.G. has been an unpaid advisor to Corvia and an investigator in the REDUCE LAP-HF II trial. F.G. is also an advisor to Abbott, AdjuCor, Alnylam, AstraZeneca, Bayer, FineHeart, Ionis and Pfizer, and a speaker for Novartis.
